Work Here?
About Vaxcyte
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2013
Overview
Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively bypass the complex defenses of bacteria while still provoking an immune response. This method sets Vaxcyte apart from traditional vaccine development approaches. The company's goal is to develop broad-spectrum vaccines that can significantly reduce the impact of bacterial diseases on global health.
Simplify's Take
What believers are saying
- Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation for pneumococcal disease prevention.
- Recent $1.5 billion public offering boosts Vaxcyte's financial resources for vaccine development.
- Growing antibiotic resistance increases demand for Vaxcyte's novel bacterial vaccines.
What critics are saying
- Competition from mRNA vaccine developers like Moderna and BioNTech is intense.
- Supply chain vulnerabilities could disrupt Vaxcyte's proprietary XpressCF™ platform.
- Emerging bacterial strains may not be covered by Vaxcyte's current vaccine candidates.
What makes Vaxcyte unique
- Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
- Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
- Vaxcyte's vaccines aim to combat bacterial infections, including pneumococcal disease and Group A Strep.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$3781M
Above
Industry Average
Funded Over
7 Rounds
Benefits
Company Equity
Stock Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 2%2 year growth
↑ 1%Vaxcyte aims to develop superior vaccines against bacterial diseases, utilizing advanced synthetic techniques like their XpressCF(TM) cell-free protein synthesis platform.
Clearbridge Investments LLC makes new $14.06 million investment in Vaxcyte, Inc. (NASDAQ:PCVX).
In the early weeks of the Covid-19 pandemic, Andrew Guggenhime joined San Carlos-based Vaxcyte Inc. as chief financial officer and chief operating officer, drawn by the company's mission to develop vaccines to prevent and treat infectious bacterial diseases.
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 10,194,175 shares of common stock and pre-funded warrants to purchase 2,427,184 shares of common stock in the offering. The shares of common stock
Vaxcyte announces closing of $1.5 billion public offering including full exercise of underwriters' option to purchase additional shares.
There are no jobs for Vaxcyte right now.
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Vaxcyte
About Vaxcyte
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2013
There are no jobs for Vaxcyte right now.
Find jobs on Simplify and start your career today
People Also Viewed
Discover companies similar to Vaxcyte